Peluso, Teresa

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 386

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., et al. (2022) · The Lancet Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 101